Transformational Immuno-Oncology Gene Therapy for Cancer Treatment

Joined December 2020
Photos and videos
$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer. See the @sitcancer announcement: scopusbiopharma.com/scopus-b…

2
3
4
128
$SCPS: “These new data suggest there is compelling potential for significant anti-tumor activity in gliomas utilizing a combination of DUET-102 with PD-1 inhibitors, such as Keytruda (Merck), Opdivo (Bristol-Myers Squibb) and Libtayo (Regeneron).” - Dr. Kortylewski, Duet
1
1
2
107
$SCPS: “Our new data demonstrate potent anti-tumor activity in malignant glioma. We are extremely excited about the significant potential of DUET-102 to be a game-changing and much-needed new treatment option for glioma patients.” - Duet CEO Alan Horsager
1
3
90
$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4th. More information on the presentation at @SITCancer: scopusbiopharma.com/scopus-b…

1
1
2
65
Scopus BioPharma (Nasdaq: $SCPS) Subsidiary— Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer. For details on this SITC $SCPS presentation, see here: scopusbiopharma.com/scopus-b…

6
3
5
Scopus BioPharma (Nasdaq: $SCPS) Completes Recapitalization Designed to Enhance Shareholder Value - Learn More About These $SCPS Transactions: scopusbiopharma.com/scopus-b…

2
2
8
Duet being positioned to go public in 2023.
3
3
Learn more about the $SCPS recapitalization and its potential enhancements to shareholder value: scopusbiopharma.com/scopus-b…

3
Scopus BioPharma (Nasdaq: $SCPS) Announces Biotechnology Industry Leader Rejoins Board of Directors - Rafi Hofstein, Ph.D. Brings Invaluable Experience to $SCPS Board. Learn More: scopusbiopharma.com/scopus-b…

3
1
3
“I am delighted to resume serving on the $SCPS Board. Having founded and nurtured many successful biotech companies, I am extremely excited about the Duet Platform, which encompasses an exceptional and comprehensive portfolio of immuno-oncology assets.” - Dr. Hofstein commented
1
3
Learn more about this exciting $SCPS appointment: scopusbiopharma.com/scopus-b…

3
The $SCPS in-person presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11 AM ET / 8 AM PT at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website.
1
3